ArticleExperimental & molecular medicine2022
Hyaluronan synthase 2, a target of miR-200c, promotes carbon tetrachloride-induced acute and chronic liver inflammation via regulation of CCL3 and CCL4.
Article in Experimental & molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- From steatosis to metastasis: microenvironmental reprogramming of the liver in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Understanding Fascial Tissue on the Molecular Level-How Its Unique Properties Enable Adaptation or Dysfunction.International journal of molecular sciences · 2025Review
- Multi-omics analysis of host airway responses in pediatric Mycoplasma pneumoniae pneumonia reveals potential mechanisms of disease exacerbation caused by co-infection.NPJ biofilms and microbiomes · 2025Article
- Molecular Imaging Probes for Early Detection and Staging of Liver Fibrosis.Chemical & biomedical imaging · 2025Review
- Identification and mechanism of key genes in inflammatory response of chronic otitis media in rats.Scientific reports · 2025Article
- Global burden of liver cirrhosis: trends from 1990-2021 and projections to 2060.Journal of health, population, and nutrition · 2025Article
- Hyaluronic Acid in Liver Fibrosis: Role in Inflammation, Tissue Remodeling, and Disease Progression.International journal of molecular sciences · 2025Review
- Exploration of the optimal concentration of quercetin liposome nanoparticles for the treatment of liver damage.BMC pharmacology & toxicology · 2025Article
- Research progress on damage-associated molecular patterns in acute kidney injury.Frontiers in immunology · 2025Review
- Rocaglamide-A mitigates LPS-induced hepatic inflammation by modulating JNK/AP-1 signaling cascade and ROS production in hepatocytes.Toxicological research · 2025Article
- Cross-disease biomarker identification reveals shared diagnostic biomarkers for IVDD and NAFLD via bulk and single-cell RNA sequencing.Frontiers in molecular neuroscience · 2025Article
- Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles.European journal of nuclear medicine and molecular imaging · 2024Article
- Article
- Knockdown of Hyaluronan synthase 2 suppresses liver fibrosis in mice via induction of transcriptomic changes similar to 4MU treatment.Scientific reports · 2024Article
- A thioacetamide-induced liver fibrosis model for pre-clinical studies in microminipig.Scientific reports · 2023Article
- Role of noncoding RNAs in liver fibrosis.World journal of gastroenterology · 2023Review
- Analysis of potential immune-related genes involved in the pathogenesis of ischemia-reperfusion injury following liver transplantation.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Liver fibrosis occurs during wound healing after repeated liver injury and is characterized by extensive extracellular matrix deposition. We previously identified hyaluronan synthase 2 (HAS2) as a driver of liver fibrosis and hepatic stellate cell (HSC) activation. Developing strategies to suppress HSC activation is key to alleviating liver fibrosis, and HAS2 is an attractive candidate for intervention. To gain insight into the molecular function of HAS2, we investigated its posttranscriptional regulation. We found that miR-200c directly targets the 3' untranslated regions of HAS2. Moreover, miR-200c and HAS2 were inversely expressed in fibrotic human and mouse livers. After establishing the direct interaction between miR-200c and HAS2, we investigated the functional outcome of regulating HAS2 expression in three murine models: CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.